cmi_logo.png
[Latest] Global Ultrapure Water Market Size/Share Worth USD 3,989 Million by 2033 at a 10.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 02, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultrapure Water Market Size, Trends and Insights By Application (Cleaning,...
YSEOP_LOGO_FINAL-PURPLE-_-YELLOW (1).png
With Support from AWS, Yseop Develops a Unique Generative AI Application for Regulatory Document Generation Across BioPharma
May 02, 2024 09:00 ET | Yseop
Yseop, with support from Amazon Web Services (AWS), announced the development of an enhanced Generative AI application for the Biopharma industry.
YPrime CNS Survey - Key eCOA Attributes
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET | Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Replay_Logo_Black_CMYK.png
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
April 30, 2024 07:00 ET | Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
23andMe_Logo_grey.png
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:05 ET | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two...
cmi_logo.png
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 18, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
April 15, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Inc_FF100_SocialToolkit_2024_1200x675
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
April 09, 2024 09:15 ET | Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
23andMe_Logo_grey.png
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024 16:05 ET | 23andMe, Inc.
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...
Celcuity+Logo.jpg
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET | Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...